PillRx only · Inhalant · Oral
Budesonide
Budesonide
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US7 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 8 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$1.468
Latest avg · Jul 22, 2026
-11%
Since Dec 17, 2025
3
Active US suppliers
90%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
39K
Rx · 2026 Q1
4.0M
Units dispensed
-40%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Cipla USA Inc. | unknown | 6 | SUPPLYING |
| Exelan Pharmaceuticals, Inc. | unknown | 3 | SUPPLYING |
| Preferred Pharmaceuticals Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jun 30, 2025RECALLRecall (Class II): Budesonide Inhalation Suspension, 0.5mg/2ml, 30 single-dose ampules per carton, five per pouch, RX Only, Manufactured b…
Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule. — Recalling firm: Cipla USA, Inc. — Distributed Nationwide in the USA
- Sep 15, 2022RECALLRecall (Class II): Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only, Rx Only, 1 envelope x five 2 mL Single Dose Ampules p…
Lack of Assurance of Sterility — Recalling firm: CIPLA — Nationwide in the USA and Puerto Rico